Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

1.

Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer.

Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, Lokeshwar VB, Lokeshwar BL.

Cancer Res. 2007 Jul 15;67(14):6854-62.

PMID:
17638896
[PubMed - indexed for MEDLINE]
Free Article
2.

Prognostic factors in prostate cancer.

Braeckman J, Michielsen D.

Recent Results Cancer Res. 2007;175:25-32. Review.

PMID:
17432552
[PubMed - indexed for MEDLINE]
3.

Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes.

Flaig TW, Nordeen SK, Lucia MS, Harrison GS, Glodé LM.

J Urol. 2007 Apr;177(4):1229-37. Review.

PMID:
17382696
[PubMed - indexed for MEDLINE]
4.

Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.

Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I.

J Urol. 2007 Feb;177(2):540-5. Review.

PMID:
17222629
[PubMed - indexed for MEDLINE]
5.

Osteopontin: a novel inflammatory mediator of cardiovascular disease.

Singh M, Ananthula S, Milhorn DM, Krishnaswamy G, Singh K.

Front Biosci. 2007 Jan 1;12:214-21. Review.

PMID:
17127294
[PubMed - indexed for MEDLINE]
6.

Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer among Finnish men in a large cancer prevention trial.

Yang HP, Woodson K, Taylor PR, Pietinen P, Albanes D, Virtamo J, Tangrea JA.

Eur J Cancer Prev. 2006 Jun;15(3):249-53.

PMID:
16679868
[PubMed - indexed for MEDLINE]
7.

Biochemical recurrence after localized treatment.

Amling CL.

Urol Clin North Am. 2006 May;33(2):147-59, v. Review.

PMID:
16631453
[PubMed - indexed for MEDLINE]
8.

Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer.

Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, Hsing A, Huang WY, Hayes RB.

Cancer Res. 2006 Apr 15;66(8):4525-30.

PMID:
16618781
[PubMed - indexed for MEDLINE]
Free Article
9.

Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence.

Cohen BL, Gomez P, Omori Y, Duncan RC, Civantos F, Soloway MS, Lokeshwar VB, Lokeshwar BL.

Int J Cancer. 2006 Sep 1;119(5):1082-7.

PMID:
16557596
[PubMed - indexed for MEDLINE]
10.

Increased expression of osteopontin contributes to the progression of prostate cancer.

Khodavirdi AC, Song Z, Yang S, Zhong C, Wang S, Wu H, Pritchard C, Nelson PS, Roy-Burman P.

Cancer Res. 2006 Jan 15;66(2):883-8.

PMID:
16424021
[PubMed - indexed for MEDLINE]
Free Article
11.

Osteopontin: role in cell signaling and cancer progression.

Rangaswami H, Bulbule A, Kundu GC.

Trends Cell Biol. 2006 Feb;16(2):79-87. Epub 2006 Jan 10. Review.

PMID:
16406521
[PubMed - indexed for MEDLINE]
12.

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.

Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ.

Urology. 2005 Dec;66(6 Suppl 1):35-63.

PMID:
16399415
[PubMed - indexed for MEDLINE]
13.

Prognostic significance of osteopontin expression in human prostate cancer.

Forootan SS, Foster CS, Aachi VR, Adamson J, Smith PH, Lin K, Ke Y.

Int J Cancer. 2006 May 1;118(9):2255-61.

PMID:
16331611
[PubMed - indexed for MEDLINE]
14.

Molecular prostate cancer pathology: current issues and achievements.

Schalken JA, Bergh A, Bono A, Foster C, Gospadarowicz M, Isaacs WB, Rubin M, Schröder F, Tribukait B, Tsukamotot T, Wiklund P.

Scand J Urol Nephrol Suppl. 2005 May;(216):82-93. Review.

PMID:
16019760
[PubMed - indexed for MEDLINE]
15.

Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease.

Routh JC, Leibovich BC.

Mayo Clin Proc. 2005 Jul;80(7):899-907. Review.

PMID:
16007895
[PubMed - indexed for MEDLINE]
16.

Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage.

Uehara H, Troncoso P, Johnston D, Bucana CD, Dinney C, Dong Z, Fidler IJ, Pettaway CA.

Prostate. 2005 Jun 15;64(1):40-9.

PMID:
15651067
[PubMed - indexed for MEDLINE]
17.

Serum interleukin-8 is elevated in men with prostate cancer and bone metastases.

Lehrer S, Diamond EJ, Mamkine B, Stone NN, Stock RG.

Technol Cancer Res Treat. 2004 Oct;3(5):411.

PMID:
15453805
[PubMed - indexed for MEDLINE]
Free Article
18.

Osteopontin: a bridge between bone and the immune system.

Gravallese EM.

J Clin Invest. 2003 Jul;112(2):147-9. Review. Erratum in: J Clin Invest. 2003 Aug;112(4):627.

PMID:
12865402
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Biochemical staging of prostate cancer.

Canto EI, Shariat SF, Slawin KM.

Urol Clin North Am. 2003 May;30(2):263-77. Review.

PMID:
12735503
[PubMed - indexed for MEDLINE]
20.

Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.

Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR.

Cancer Res. 2002 Jun 15;62(12):3417-27.

PMID:
12067984
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk